
Debt Finance
Banking & Finance
Capital Markets
High Yield
Rachael L. Lichman is a debt finance partner at Kirkland & Ellis LLP, based in the Houston office. With extensive experience in banking and finance, she represents borrowers, issuers, and financial institutions in various secured and unsecured financings, including acquisition financings and high-yield debt offerings. Rachael also specializes in debt restructurings and workouts. Her notable clients include Antero Midstream Partners, EQT Corporation, and WeWork Inc. Rachael holds a JD with Highest Honors from the University of Texas at Austin School of Law and a BA in Political Science from Duke University.
Rachael L. Lichman's representative experience includes advising:


- Kirkland & Ellis advised Amicus Therapeutics (Nasdaq: FOLD) on its agreed all-cash sale to BioMarin (Nasdaq: BMRN) at $14.50 per share, valuing Amicus at about $4.8bn. - The deal was unanimously approved by both boards, with Amicus’ board recommending stockholders vote in favour; expected to close in Q2 2026, subject to regulatory and Amicus stockholder approvals and other customary conditions. - The acquisition adds Galafold (Fabry) and Pombiliti + Opfolda (Pompe) to BioMarin’s lysosomal storage disorder portfolio, and includes Amicus’ U.S. rights to DMX-200 (Phase 3) for FSGS.
Dec 19 2025
5B
M&A

Partner
2021 – Unknown
Partner
2017 – 2021

- Waters Corporation acquired the target/assets from Becton, Dickinson and Company in a merger on not available. - Deal value was 17500000000 Sector: Life Sciences; Location: USA. - On the acquirer side, counsel was not available; lawyers included David Klein, Daniel Wolf, Allie Wein, Steven Choi, Dean Shulman, Liam Murphy, Rachel Malhiet, Rob Fowler, Rebekah Kostelak, Matthew Antinossi, Sophia Hudson, Jennifer Lee, Zoey Hitzert, Rachael Lichman, Charles Martin, Jeff Seroogy, Amy Barber, Andrea Murino, Psalm Cheung, Will Richmond, Dennis Williams.
Jul 14 2025
18B
M&A
1 min
BA in Political Science magna cum laude, Duke University
2005